Loading...
Zosano Pharma Corporation
ZSAN•NASDAQ
HealthcareBiotechnology
$0.56
$0.00(0.00%)
Zosano Pharma Corporation (ZSAN) Stock Overview
Explore Zosano Pharma Corporation’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ZSANStats details for ZSAN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ZSANAnalyst Recommendations details for ZSAN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
CEO
Steven Lo
Employees
40
Headquarters
34790 Ardentech Ct, Fremont, CA
Founded
2015